Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W06T | ISIN: US7496031060 | Ticker-Symbol: N/A
1-Jahres-Chart
RJD GREEN INC Chart 1 Jahr
5-Tage-Chart
RJD GREEN INC 5-Tage-Chart
ACCESS Newswire
166 Leser
Artikel bewerten:
(1)

RJD Green, Inc. Timely Filed Q1 Quarterly Report on OTC Markets; Reflecting Three Month Revenue of $1,334,355 and $214,253 EBITDA as of November 30, 2024

Finanznachrichten News

TULSA, OK / ACCESS Newswire / January 17, 2025 / RJD Green Inc. (OTC PINK:RJDG), is a publicly traded company that operates as a holding company focusing on acquiring and managing assets, while actively exploring potential acquisitions within the medical management services and introducing additional products and services in our Silex Holdings Division. RJDG announced the results of its Quarterly Report for Q1 Ended, November 30, 2024.

Ron Brewer, CEO of RJD Green, said: "Our results reflect that as of November 30, 2024, for the first quarter of 2025, we are on course for over $6,000,000 in annual revenue prior to the expected additional revenue growth from additional products and services. Through Quarter One, revenue is $1,334,355 with EBITDA OF $214,253, assets are $2,677,774 with current assets of $2,2,53,933, and no long-term liabilities and $289,223 in current liabilities.

We are focused on finding ways to monetize our assets and increase shareholder value fully. RJDG is currently actively engaged in acquisition efforts that are symmetrical with our current operations in the IOSoft Services Division, which provides management and technical products for the healthcare sector.

The Silex Holding Division has aggressively entered into the marketing of additional products complementing our current primary focus on cabinetry and stone products such as counter tops. The products include commercial and residential doors, trim and molding, hardware, and fireplace units.

Our markets include commercial projects and multifamily housing in a four-state regional market, while covering most of the state of Oklahoma for home builders, remodel companies, and retail clients. We look forward to seeing the fruit of our efforts in the 2025 fiscal year, as we currently have over $1,600,000 in backlog.

Additionally, Silex Holdings purchased state-of-the-art stone fabrication assets with the expectation of launching a new division in the fourth quarter of 2024.The equipment purchase was closed with internal capital and no debt. Unfortunately, the operating agreement between the two companies has lingered with the launch of the new unit now targeted for February 20th at this time.

To our valued shareholders, we will continue to execute the business model to create substantive growth through acquiring assets and small-cap acquisitions that meet our criteria."

About RJD Green, Inc.

The Company operates as a holding company with a focus of acquiring and managing assets and companies. RJD Green operates in three divisions: RJD Green Healthcare Services Division, which owns IOSoft Services, our division that provides discrete payment technologies, services and software that can be integrated into targeted offerings for healthcare provider networks, hospitals, healthcare payers and individual providers; Earthlinc Environmental Services Division, which provides green environmental services and technologies; and Silex Holdings Division, which is focused in specialty construction and industrial services. The initial operations, Silex Interiors, fills a market niche between the Home Depots and local contractors. Silex manufactures and installs granite and other counter tops, cabinets and related products to the residential builder, commercial contractor, remodel contractor and DIY customer.

Visit http://www.rjdgreen.com.

Forward-Looking Statement:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events of future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements.

Company Contact:

RJD Green, Inc.
Ron Brewer, CEO
918.551.7883
ronb@rjdgreen.com

Public Relations:

Equitas Group
Kenneth Quist
(918) 998-9611
thekwisterone@gmail.com

SOURCE: RJD Green, Inc.



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.